USD $1.00-10.00 / Kilogram
USD $100.00-150.00 / Kilogram
USD $100.00-150.00 / Kilogram
USD $1.00-10.00 / Kilogram
USD $5.00-20.00 / Kilogram
USD $100.00-150.00 / Kilogram
USD $100.00-150.00 / Kilogram
USD $100.00-150.00 / Kilogram
USD $10.00-10.00 / Gram
product name: | finasteride |
synonyms: | (5alpha,17beta)-(1,1-dimethylethyl)-3-oxo-4-azaandrost-1-ene-17-carboxamide;17beta-(n-tert-butylcarbamoyl)-4-aza-5alpha-androst-1-en-3-one;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5-alpha,17-be;4-azaandrost-1-ene-17-carboxamide,n-(1,1-dimethylethyl)-3-oxo-,(5alpha,17beta;l-652,931;mk-0906;n-tert-butyl-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide;1,(5-alpha)-androstan-4-aza-3-one-17-beta-(n-tert-butyl-carboxamide) |
cas: | 98319-26-7 |
mf: | c23h36n2o2 |
mw: | 372.54 |
einecs: | |
product categories: | active pharmaceutical ingredients;api;biochemistry;steroids;steroids (others);intermediates & fine chemicals;pharmaceuticals;vitamin ingredients;intracellular receptor;steroid and hormone;proscar;hormone drugs |
mol file: | 98319-26-7.mol |
finasteride chemical properties |
melting point | 253 °c |
alpha | 405 -59° (c = 1 in methanol) |
storage temp. | store at rt |
solubility | dmso: 32 mg/ml, soluble |
form | solid |
color | white to beige |
water solubility | insoluble |
merck | 14,4082 |
cas database reference | 98319-26-7(cas database reference) |
safety information |
hazard codes | xn,t,xi |
risk statements | 22-61-60-36/37/38 |
safety statements | 36/37/39-45-53-36-26-24/25 |
wgk germany | 3 |
rtecs | cl5245000 |
hazardous substances data | 98319-26-7(hazardous substances data) |
msds information |
provider | language |
---|---|
sigmaaldrich | english |
finasteride usage and synthesis |
indications and usage |
finasteride is a basic drug to treat benign prostatic hyperplasia and prostatitis, a synthetic 4-nitrogen steroid hormone compound and a sex hormone drug. it is used for benign prostatic hyperplasia, men's prostatic fat and other diseases. finasteride is the only oral drug approved by the us food and drug administration (fda) to treat male pattern baldness. |
mechanisms of action | finasteride can selectively inhibit 5α-reductase, changing the conversion process of testosterone into 5α dihydrotestosterone (dht), decreasing androgen levels in prostate cells, and prostate-specific antigens in serum, decreasing prostate swelling, and increasing urine flow rate, thereby alleviating the symptoms of prostatic hyperplasia. it acts by selectively blocking androgen stimulation of the prostate, but affects sexual function very rarely. meanwhile, due to blocking of testosterone conversion and reduced synthesis of dihydrotestosterone, it can reduce dihydrotestosterone levels in the serum and scalp hair follicles, recovering the function of previously inhibited hair follicles, promoting hair growth and preventing loss. |
chemical properties | off-white crystalline powder |
uses | inhibitor of 5α-reductase, the enzyme which converts testosterone to the more potent androgen, 5α-dihydrotestosterone. antialopecia agent. |
uses | anti-androgen, alpha-reductase inhibitor |
uses | treatment of benign prostatic hyperplasia and androgenetic alopecia |
uses | inhibitor of 5a-reductase, the enzyme which converts testosterone to the more potent androgen, 5a-dihydrotestosterone. antialopecia agent |
definition | chebi: an aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia. |
biological activity | antiandrogen that inhibits type ii 5 α reductase (ic 50 = 65 nm). suppresses the conversion of testosterone to dihydrotestosterone. reduces prostatic dihydrotestosterone levels and prostate size in vivo . orally active. |